R
ROQ
vs
F
FTSE All Share Index
Over the past 12 months, ROQ has outperformed FTSE All Share Index, delivering a return of -38% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
ROQ vs FTSE All Share Index
Performance Gap
ROQ vs FTSE All Share Index
Performance By Year
ROQ vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Roquefort Therapeutics PLC
Glance View
Roquefort Therapeutics plc operates as an investment company. The firm is developing products through the pre-clinical phase. The firm operates through its subsidiary Lyramid Pty Ltd (Lyramid). Lyramid is a pre-clinical biotechnology company focused on developing first-in-class Midkine inhibiting ribonucleic acid (RNA) therapeutic drugs for the treatment of cancer, chronic inflammatory, and autoimmune disorders, as well as lung diseases such as COVID-19. Lyramid has identified the therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid also intends to develop its oligonucleotide, and potentially antibody, drugs through preclinical and early clinical development.
